WO2000030624A2 - Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus - Google Patents

Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus Download PDF

Info

Publication number
WO2000030624A2
WO2000030624A2 PCT/EP1999/008795 EP9908795W WO0030624A2 WO 2000030624 A2 WO2000030624 A2 WO 2000030624A2 EP 9908795 W EP9908795 W EP 9908795W WO 0030624 A2 WO0030624 A2 WO 0030624A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
atoms
het
insulin
treatment
Prior art date
Application number
PCT/EP1999/008795
Other languages
French (fr)
Other versions
WO2000030624A3 (en
Inventor
Rolf Gericke
Manfred Baumgarth
Klaus Minck
Didier Mesangeau
Liliane Doare
Micheline Kergoat
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to HU0104418A priority Critical patent/HUP0104418A2/en
Priority to AU15535/00A priority patent/AU1553500A/en
Priority to JP2000583507A priority patent/JP2002530325A/en
Priority to CA002352154A priority patent/CA2352154A1/en
Priority to BR9915667-9A priority patent/BR9915667A/en
Priority to KR1020017006615A priority patent/KR20010080597A/en
Priority to EP99958047A priority patent/EP1131064A2/en
Publication of WO2000030624A2 publication Critical patent/WO2000030624A2/en
Publication of WO2000030624A3 publication Critical patent/WO2000030624A3/en
Priority to NO20012563A priority patent/NO20012563D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Definitions

  • the invention relates to the use of benzoylguanidines of the formula I
  • R 1 is A
  • R 2 is Het, CnFmH mOp, R 4 , OR 4 , OH, benzyl, CN, Hal, SO q -R 5 ,
  • Ph, O-Ph, O-Het, NH-Het, NH 2 , NHA, NA 2 or NH-Ph, R 3 is S0 2 A,
  • R 4 is a straight-chain or branched alkyl radical having 1 to 8 C atoms or cycloalkyl having 3 to 8 C atoms which can be unsubstituted or mono-, di- or trisubstituted by A
  • R 5 is A or Ph
  • A, A' in each case independently of one another are alkyl having 1 to
  • Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by Hal, CF 3 , A, CN, N0 2 , NH 2 and/or carbonyl oxygen, Hal is F, Cl, Br o l,
  • Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF 3 , NH 2 , NHA or NA 2 , m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3, p is 0 or 1 , q is 0, 1 or 2, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus. and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus.
  • the compounds of formula I are known from EP 0 699 666, EP 0 699 663, EP 0 743 301 , EP 0 704431 , EP 0 758 644, EP 0 699 660, EP 0 725 062, EP 0 708 088, EP 0 694 537 and EP 0723 963. They are potent inhibitors of the cellular sodium-proton-antiporter (Na + /H + -exchanger).
  • Benzoylguanidines with other substitution patterns are discribed e.g. in EP 0 589 336 as inhibitors of the cellular sodium-proton-antiporter, which shows an increased level in diabetes.
  • pyrazinoylguanidines for the treatment of diabetes mellitus is disclosed in WO 97/21438.
  • the invention was based on the object of finding compounds having useful properties, in particular those which can be used for the production of medicaments.
  • NIDDM non-insulin-dependent diabetes mellitus
  • the compounds of the formula I and their salts can be used for the production of a medicament for lowering and/or controlling the blood sugar levels of NIDDM persons. Additionally, the compounds of the formula I and their salts can be used for the production of a medicament for lowering and/or controlling the levels of insulin, free fatty acids and triglycerides of NIDDM persons.
  • the invention thus relates to the use of benzoylguanidines of the formula I wherein the compounds are selected from the group
  • Solvates means addition compounds with e.g. water or alcoholes.
  • Alkyl has 1 to 6, preferably 1 , 2, 3, 4, 5 or 6 C atoms.
  • Alkyl is therefore in particular, for example, methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl,
  • R preferably means alkyl having 1-6 C atoms, preferably e.g. methyl, ethyl, propyl or isopropyl, most preferably methyl.
  • R 3 means S0 2 A', wherein A preferably is e.g. methyl, ethyl, propyl, isopropyl or butyl, most preferably R 3 means SO 2 CH 3 .
  • Het is preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyi, furthermore preferably 1 ,2,3-triazol-1-, -4- or -5- yl, 1 ,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1 ,2,3-oxadiazol-4- or -5-yl, 1 ,2,4-oxadiazol-3- or 5-yl, 1 ,3,4-thiadiazol-2- or -5-yl, 1 ,2,4-thiadiazol-3- or -5-yl,
  • 6- or 7-benzothiazolyl 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7- be ⁇ zo-2,1 ,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-,
  • heterocyclic radicals can also be partially or completely hydrogenated.
  • Het can thus, for example, also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1 ,3- dioxoian-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidi ⁇ yl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrazolyl, tetrahydro-1-, -3- or -4-pyrazoly
  • Het means 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1- pyrrolidinyl, 1-pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl; the most preferred meaning is 1-pyrrolyl.
  • o C n F m H 2n+ ⁇ -mOp is preferably OCF 3 , OCH 2 F, OCHF 2 , CF 3 C 2 F 5 or partially fluorinated alkyl having 1-4 C atoms, CH 2 F, CHF 2 , C 2 HF 4 , C 2 H 2 F 3 or C 2 H 4 F.
  • R 4 is preferably a straight-chain or branched alkyl radical having 1 to 8 C
  • R is noncyclic, the radical is then, preferably, one of the alkyl radicals which are also preferred for A.
  • Particularly preferred cycloalkyl radicals which can be R 4 are cyclopropyi, cyclobutyl, cyclopentyl or cyclohexyl, or their derivatives which are 20 substituted once by A, in particular methyl, ethyl or isopropyl.
  • R 2 is preferably e.g. F, Cl, Br, methyl, ethyl, propyl, iso-propyl, 2-butyl, -(CH 2 ) 4 -CH 3 , cyclobutyl, cyclohexyl, p-tolyl, 4-chlorophenyl, 2,4-dichloro- phenyl, 4-fluorophenyl, 3,5-bis(trifluoromethyl)phenyl, 3,5-dichlorophenyl,
  • the invention relates in particular to the use of those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
  • Some preferred groups of compounds can be expressed by the following subformulae la to 1i, which correspond to the formula I and in which the radicals not ⁇ Q described in greater detail have the meaning indicated in the formula I, but in which
  • R 3 is S0 2 CH 3 ;
  • R 3 is S0 2 CH 3 ;
  • R 3 is S0 2 CH 3 ;
  • R 2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl;
  • R 1 is methyl or ethyl
  • R J is SO 2 A *
  • R 4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A
  • R 5 is A or Ph
  • A' is alkyl having 1 to 6 C atoms
  • Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by Hal, CF 3 , A, CN, N0 2 , NH 2 and/or carbonyl oxygen,
  • Hal isF, Cl, Brorl, Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF 3 , NH 2 , NHA or NA 2 , m is 1, 2, 3, 4, 5, 6, 7, but at most 2n+1, n is 1,2 or 3, p isOorl; q is 0 or 2;
  • R 1 is methyl or ethyl, R 3 is S0 2 CH 3 ;
  • R 2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyi, 1- pyrrolyl, pyridyl, oxodihydropyridyl, benzimidazolyl, C n FmH 2 n+ ⁇ -mOp or R ;
  • R 4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, A is alkyl having 1 to 6 C atoms, m is 1,2,3,4, 5,6, 7, but at most 2n+1, n is 1,2 or 3, p isOorl;
  • R 1 is methyl or ethyl, R 3 is S0 2 CH 3 ;
  • R 2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidi ⁇ yl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl, CF 3 , OCF 3 or alkyl having 1 to 6 C atoms;
  • R 3 is S0 2 CH 3 ;
  • R 2 is 1-pyrrolyl, CF 3 , OCF 3 or alkyl having 1 to 4 C atoms
  • R 3 is S0 2 A
  • R 2 is Het, R 4 , OR 4 , OH, benzyl, CN, F, Cl,
  • R ⁇ 4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, R 5 is A or Ph,
  • A, A' is alkyl having 1 to 6 C atoms
  • Het is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyi, 1- pyrrolyl, pyridyl, oxodihydropyridyl, benzimidazolyl, which can be substituted once, twice or three times by Hal, CF 3 , A, CN, N0 2 , NH 2 and/or carbonyl oxygen, Hal is F, Cl, Br or l, Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF 3 , NH 2 , NHA or NA 2 , m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3, p is 0 or 1 ; q is 0 or 2; and/or their physiologically acceptable salts and solvates.
  • the compounds of formula I can be used in the form of salts derived from inorganic or organic acids or bases.
  • a base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation.
  • possible acids are in particular those which yield physiologically acceptable salts.
  • inorganic acids can be used, e.g.
  • sulfuric acid nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, further organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocydic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
  • compounds of the formula I can be converted using bases (e.g. sodium or potassium hydroxide or carbonate) into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts.
  • bases e.g. sodium or potassium hydroxide or carbonate
  • test results of the antidiabetic activity of some representative compounds of the formula I are compiled in Table I which follows.
  • the compounds were administered by oral route on an animal model of diabetes (NOSTZ rats) showing a moderate diabetic state.
  • the compounds were studied using the procedure that is: determination of basal glycemia, lactatemia and insulinemia before treatment day 0, 2 hours after acute (day 1) and 2 hours after the last administration of the chronic treatment (once a day during 4 days) of the compounds at 20 mg/kg.
  • the pharmacological data confirm that the tested compounds at 20 mg/kg decreased significantly the fasting plasma glucose after acute and chronic treatment.
  • the invention further relates to the use of the compounds of the formula I and/or their physiologically acceptable salts for the production of pharmaceutical preparations for the treatment of non-insulin-dependent diabetes mellitus, in particular in a non-chemical way.
  • they can be brought into a suitable dose form together with at least one solid, liquid and/or semiliquid excipient or auxiliary and if appropriate in combination with one or more of the further active compounds.
  • the invention further relates to a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus containing at least one compound of the formula I and/or one of its physiologically acceptable salts or solvates.
  • the invention further relates to a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus, characterized in that it contains at least one compound selected from the group a) N-diaminomethylene-2-methyl-4-(1-pyrrolyl)-5-methylsulfonyl- enzamide, b) N-diaminomethyle ⁇ e-2-methyl-4-trifluoromethyl-5-methylsulfonyl- benzamide, c) N-diaminomethylene-2-methyl-4-isopropyl-5-methylsulfony- benzamide, and/or one of its physiologically salts or solvates.
  • a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus characterized in that it contains at least one compound selected from the group a) N-diaminomethylene-2-methyl-4-(1-pyrrolyl)-5-methylsulfonyl- enzamide, b) N-diaminomethyle ⁇ e-2-methyl
  • preparations can be used as medicaments in human or veterinary medicine.
  • Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly.
  • Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used in particular for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, and in addition suspensions, emulsions or implants are used for parentaral administration, and ointments, creams or powders are used for topical application.
  • the compounds of formula I can aiso be lyophiiized and the lyophilizates obtained used, for example, for the production of injection preparations.
  • the preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.
  • auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.
  • the compounds of formula I according to the invention are generally administered in analogy to other known commercially available preparations for the indications claimed (e.g. metformine or amiioride), preferably in doses of between 0.1 mg and 500 mg, in particular between 5 and 300 mg per dose unit.
  • the daily dose is preferably between approximately 0.01 and 250 mg/kg, in particular between 0.02 and 100 mg/kg of body weight.
  • the substances according to the formula I are generally preferably administered in doses of between approximately 1 and 500 mg, in particular between 5 and 100 mg per dose unit.
  • the daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight.
  • the specific dose for each patient depends on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy relates. Oral administration is preferred.
  • a solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 I of double-distilled water using 2 N hydrochloric acid, sterile-filtered, filled into injection vials and lyophilized under sterile conditions, and the vials are aseptically sealed. Each injection vial contains 5 mg of active compound.
  • a mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.
  • a solution is prepared from 1 g of an active compound of the formula I, 9.38 g of NaH 2 P0 4 .2H 2 0, 28.48 g of Na 2 HP0 4 .12H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The pH is adjusted to 6.8, and the solution is made up to 1 I and sterilized by irradiation.
  • 500 mg of an active compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
  • Example F Coated tablets
  • Example E tablets are pressed which are then coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth and colourant.
  • a solution of 1 kg of active compound of the formula I in 60 i of double- distilled water is steriie- filtered, filled into ampoules and lyophilized under sterile conditions, and the ampoules are aseptically sealed. Each ampoule contains 10 mg of active compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

(57) Abstract The invention relates to the use of benzoylguanidines of formula (I) wherein R1 is A; R2 is Het, C¿n?FmH2n+1-mOp, R?4, OR4¿, OH, benzyl, CN, Hal, SO¿q-R?5, Ph, O-Ph, O-Het, NH-Het, NH¿2?, NHA, NA2 or NH-Ph; R?3¿ is SO¿2A'; R?4 is a straight-chain or branched alkyl radical having 1 to 8 C atoms or cycloalkyl having 3 to 8 C atoms which can be unsubstituted or mono-, di- or trisubstituted by A; R5 is A or Ph; A, A' in each case independently of one another are alkyl having 1 to 6 C atoms, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus.

Description

Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
The invention relates to the use of benzoylguanidines of the formula I
Figure imgf000003_0001
R1 is A,
R2 is Het, CnFmH mOp, R4, OR4, OH, benzyl, CN, Hal, SOq-R5,
Ph, O-Ph, O-Het, NH-Het, NH2, NHA, NA2 or NH-Ph, R3 is S02A,
R4 is a straight-chain or branched alkyl radical having 1 to 8 C atoms or cycloalkyl having 3 to 8 C atoms which can be unsubstituted or mono-, di- or trisubstituted by A, R5 is A or Ph, A, A' in each case independently of one another are alkyl having 1 to
6 C atoms, Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by Hal, CF3, A, CN, N02, NH2 and/or carbonyl oxygen, Hal is F, Cl, Br o l,
Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF3, NH2, NHA or NA2, m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3, p is 0 or 1 , q is 0, 1 or 2, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus. and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus.
The compounds of formula I are known from EP 0 699 666, EP 0 699 663, EP 0 743 301 , EP 0 704431 , EP 0 758 644, EP 0 699 660, EP 0 725 062, EP 0 708 088, EP 0 694 537 and EP 0723 963. They are potent inhibitors of the cellular sodium-proton-antiporter (Na+/H+-exchanger).
Benzoylguanidines with other substitution patterns are discribed e.g. in EP 0 589 336 as inhibitors of the cellular sodium-proton-antiporter, which shows an increased level in diabetes.
The use of pyrazinoylguanidines for the treatment of diabetes mellitus is disclosed in WO 97/21438.
The invention was based on the object of finding compounds having useful properties, in particular those which can be used for the production of medicaments.
It has been found that the compounds of the formula I and their salts have particularly useful pharmacological properties combined with good tolerability, as, in particular, they can be used for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
Moreover, the compounds of the formula I and their salts can be used for the production of a medicament for lowering and/or controlling the blood sugar levels of NIDDM persons. Additionally, the compounds of the formula I and their salts can be used for the production of a medicament for lowering and/or controlling the levels of insulin, free fatty acids and triglycerides of NIDDM persons.
The activity of the compounds of formula 1 which can be used for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus was confirmed experimentally for some representative ^ Q compounds of the formula I. The pharmacological test data are compiled in Table I.
The invention thus relates to the use of benzoylguanidines of the formula I wherein the compounds are selected from the group
-I E a) N-diaminomethylene-2-methyl-4-(1 -pyrrolyl)-5-methylsulfonyl- benzamide, b) N-diaminomethylene-2-methyl-4-trifluoromethyl-5-methyisulfonyl- benzamide,
20 c) N-diaminomethyiene-2-methyl-4-isopropyl-5-methylsulfonyl- benzamide, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin-dependent diabetes mellitus.
25
Solvates means addition compounds with e.g. water or alcoholes.
For all radicals which occur several times, such as, for example, A, it holds 30 true that their meanings are independent of one another.
Alkyl has 1 to 6, preferably 1 , 2, 3, 4, 5 or 6 C atoms. Alkyl is therefore in particular, for example, methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyl,
35
1 ,1-, 1 ,2- or 2,2-dimethylpropyl, 1-ethyipropyl, hexyl, 1-, 2-, 3- or 4- methylpentyl, 1 ,1-, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2- ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylpropyl.
R preferably means alkyl having 1-6 C atoms, preferably e.g. methyl, ethyl, propyl or isopropyl, most preferably methyl. R3 means S02A', wherein A preferably is e.g. methyl, ethyl, propyl, isopropyl or butyl, most preferably R3 means SO2CH3.
Het is preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyi, furthermore preferably 1 ,2,3-triazol-1-, -4- or -5- yl, 1 ,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1 ,2,3-oxadiazol-4- or -5-yl, 1 ,2,4-oxadiazol-3- or 5-yl, 1 ,3,4-thiadiazol-2- or -5-yl, 1 ,2,4-thiadiazol-3- or -5-yl, 1 ,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4-H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5- 6- or 7- benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7- indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzoisoxazolyl, 2-, 4-, 5-,
6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7- beπzo-2,1 ,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-,
7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 2-, 4-, 5-, 6-, 7- or 8- quinazolinyi. The heterocyclic radicals can also be partially or completely hydrogenated. Het can thus, for example, also be 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1 ,3- dioxoian-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidiπyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5- pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1 ,4-dihydro-1-, -2-, -3- or -4- pyridyl, 1 ,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpho!inyl, tetrahydro-2-, -3- or -4-pyranyl, 1 ,4- dioxanyl, 1 ,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1 ,2,3,4- tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1 ,2,3,4-tetrahydro-l-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl. ^ Most preferably, Het means 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1- pyrrolidinyl, 1-pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl; the most preferred meaning is 1-pyrrolyl.
-, o CnFmH2n+ι-mOp is preferably OCF3, OCH2F, OCHF2, CF3 C2F5 or partially fluorinated alkyl having 1-4 C atoms, CH2F, CHF2, C2HF4, C2H2F3 or C2H4F.
R4 is preferably a straight-chain or branched alkyl radical having 1 to 8 C
A C . atoms or cycloalkyl having 3 to 8 C atoms. If R is noncyclic, the radical is then, preferably, one of the alkyl radicals which are also preferred for A. Particularly preferred cycloalkyl radicals which can be R4 are cyclopropyi, cyclobutyl, cyclopentyl or cyclohexyl, or their derivatives which are 20 substituted once by A, in particular methyl, ethyl or isopropyl.
R2 is preferably e.g. F, Cl, Br, methyl, ethyl, propyl, iso-propyl, 2-butyl, -(CH2)4-CH3, cyclobutyl, cyclohexyl, p-tolyl, 4-chlorophenyl, 2,4-dichloro- phenyl, 4-fluorophenyl, 3,5-bis(trifluoromethyl)phenyl, 3,5-dichlorophenyl,
25 phenyl, 2-furyl, SMe, SEt, SPr, S-iso-propyl, S-tert.-butyl, S-(3-chloro- phenyl), S-(2-chlorophenyl), S-(4-chlorophenyl), S-phenyl, S-(4-pyridyl), benzyloxy, OH, methoxy, ethoxy, iso-propyloxy, cyclopentyloxy, cyclohexyloxy, tert.-butyloxy, phenoxy, 2-chlorophenoxy, 3-chlorophenoxy, 30 4-chlorophenoxy, 3-pyridyloxy, 1-pyrrolidinyl, 1-piperidinyl, 3-hydroxy-1- piperidiπyl, 4-amino-1-piperidinyl, 1-imidazolyl, 1-benzimidazolyl, 2-methyl- 1-imidazolyl, 1-pyrazolyl, 1-pyrrolyl, amino, anilino, 2-pyridylamino or 2- pyrimidylamino. For the whole invention, it holds true that all radicals which occur several times can be identical or different, i.e. are independent of one another.
Accordingly, the invention relates in particular to the use of those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following subformulae la to 1i, which correspond to the formula I and in which the radicals not ^ Q described in greater detail have the meaning indicated in the formula I, but in which
in la R is methyl or ethyl;
1 5 in lb R3 is S02CH3;
in lc R1 is methyl or ethyl,
R3 is S02CH3;
20 in Id Het is 1-imidazolyl, 1-piperazinyi, 1-piperidyl, 1-pyrrolidinyl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl;
in le R1 is methyl or ethyl,
25 R3 is S02CH3; R2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl;
30 in If R1 is methyl or ethyl,
RJ is SO2A*
R2 Het, CnFmH2n+ι-mOp, R4, OR4, OH, benzyl, CN, F, Cl, SOqR5, Ph, O-Ph, O-Het, NH-Het, NH2, NHA, NA2 or NH-Ph;
35 R4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, R5 is A or Ph, A, A' is alkyl having 1 to 6 C atoms,
Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by Hal, CF3, A, CN, N02, NH2 and/or carbonyl oxygen,
Hal isF, Cl, Brorl, Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF3, NH2, NHA or NA2, m is 1, 2, 3, 4, 5, 6, 7, but at most 2n+1, n is 1,2 or 3, p isOorl; q is 0 or 2;
lg R1 is methyl or ethyl, R3 is S02CH3;
R2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyi, 1- pyrrolyl, pyridyl, oxodihydropyridyl, benzimidazolyl, CnFmH2n+ι-mOp or R ; R4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, A is alkyl having 1 to 6 C atoms, m is 1,2,3,4, 5,6, 7, but at most 2n+1, n is 1,2 or 3, p isOorl;
in Ih R1 is methyl or ethyl, R3 is S02CH3; R2 is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidiπyl, 1- pyrrolyl, pyridyl, oxodihydropyridyl or benzimidazolyl, CF3, OCF3 or alkyl having 1 to 6 C atoms;
in li R1 is methyl or ethyl,
R3 is S02CH3;
R2 is 1-pyrrolyl, CF3, OCF3 or alkyl having 1 to 4 C atoms
in Ij R1 is methyl or ethyl,
R3 is S02A;
R2 is Het,
Figure imgf000010_0001
R4, OR4, OH, benzyl, CN, F, Cl,
SOπR5, Ph, O-Ph, O-Het, NH-Het, NH2l NHA, NA2 or NH-Ph;
R ι4 is a straight-chain or branched alkyl radical having 1 to 6 C atoms or cycloalkyl having 3 to 6 C atoms which can be unsubstituted or monosubstituted by A, R5 is A or Ph,
A, A' is alkyl having 1 to 6 C atoms, Het is 1-imidazolyl, 1-piperazinyl, 1-piperidyl, 1-pyrrolidinyi, 1- pyrrolyl, pyridyl, oxodihydropyridyl, benzimidazolyl, which can be substituted once, twice or three times by Hal, CF3, A, CN, N02, NH2 and/or carbonyl oxygen, Hal is F, Cl, Br or l, Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF3, NH2, NHA or NA2, m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3, p is 0 or 1 ; q is 0 or 2; and/or their physiologically acceptable salts and solvates.
The compounds of formula I can be used in the form of salts derived from inorganic or organic acids or bases. A base of the formula I can be converted into the associated acid addition salt using an acid, for example by reaction of equivalent amounts of the base and of the acid in an inert solvent such as ethanol and subsequent evaporation. For this reaction, possible acids are in particular those which yield physiologically acceptable salts. Thus inorganic acids can be used, e.g. sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, further organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocydic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g. formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane- or ethane- sulfonic acid, ethanedisulfonic acid, 2-hydroxyethane-suifonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenemono- and disulfonic acids, and laurylsulfuric acid. Salts with physiologically unacceptable acids, e.g. picrates, can be used for the isolation and/or purification of the compounds of the formula I.
On the other hand, compounds of the formula I can be converted using bases (e.g. sodium or potassium hydroxide or carbonate) into the corresponding metal salts, in particular alkali metal or alkaline earth metal salts, or into the corresponding ammonium salts.
The test results of the antidiabetic activity of some representative compounds of the formula I are compiled in Table I which follows. The compounds were administered by oral route on an animal model of diabetes (NOSTZ rats) showing a moderate diabetic state.
Experiments were carried out on adult male rats 300-500 g, housed in groups of 5 under standard conditions. Diabetes was induced by injection of streptozotocin (100 mg/ kg body weight intravenously) on day of birth. As adult, NOSTZ rats present a NIDDM with the following characteristics (Portha - Diabetologia 17, 313- 377, 1979):
- fasting hyperglycemia 180-200 mg/dl
- glucose intolerance
- specific failure of insulin secretion in response to glucose.
All drugs tested were suspended in an arabic gum solution and administered by oral route once a day during 4 days.
The compounds were studied using the procedure that is: determination of basal glycemia, lactatemia and insulinemia before treatment day 0, 2 hours after acute (day 1) and 2 hours after the last administration of the chronic treatment (once a day during 4 days) of the compounds at 20 mg/kg.
Table I
Antidiabetic activity of representative compounds of the formula I on NOSTZ diabetic rats (20 mg/kg p.o., effects [%])
Figure imgf000012_0001
Figure imgf000012_0002
The pharmacological data confirm that the tested compounds at 20 mg/kg decreased significantly the fasting plasma glucose after acute and chronic treatment.
The invention further relates to the use of the compounds of the formula I and/or their physiologically acceptable salts for the production of pharmaceutical preparations for the treatment of non-insulin-dependent diabetes mellitus, in particular in a non-chemical way. In this context, they can be brought into a suitable dose form together with at least one solid, liquid and/or semiliquid excipient or auxiliary and if appropriate in combination with one or more of the further active compounds.
The invention further relates to a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus containing at least one compound of the formula I and/or one of its physiologically acceptable salts or solvates.
The invention further relates to a pharmaceutical preparation for the treatment of non-insulin-dependent diabetes mellitus, characterized in that it contains at least one compound selected from the group a) N-diaminomethylene-2-methyl-4-(1-pyrrolyl)-5-methylsulfonyl- enzamide, b) N-diaminomethyleπe-2-methyl-4-trifluoromethyl-5-methylsulfonyl- benzamide, c) N-diaminomethylene-2-methyl-4-isopropyl-5-methylsulfony- benzamide, and/or one of its physiologically salts or solvates.
These preparations can be used as medicaments in human or veterinary medicine. Possible excipients are organic or inorganic substances which are suitable for enteral (e.g. oral) or parenteral administration or topical application and do not react with the novel compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc and petroleum jelly. Tablets, pills, coated tablets, capsules, powders, granules, syrups, juices or drops are used in particular for oral administration, suppositories are used for rectal administration, solutions, preferably oily or aqueous solutions, and in addition suspensions, emulsions or implants are used for parentaral administration, and ointments, creams or powders are used for topical application. The compounds of formula I can aiso be lyophiiized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins.
The compounds of formula I according to the invention are generally administered in analogy to other known commercially available preparations for the indications claimed (e.g. metformine or amiioride), preferably in doses of between 0.1 mg and 500 mg, in particular between 5 and 300 mg per dose unit. The daily dose is preferably between approximately 0.01 and 250 mg/kg, in particular between 0.02 and 100 mg/kg of body weight.
In this case, the substances according to the formula I are generally preferably administered in doses of between approximately 1 and 500 mg, in particular between 5 and 100 mg per dose unit. The daily dose is preferably between approximately 0.02 and 10 mg/kg of body weight. The specific dose for each patient, however, depends on all sorts of factors, for example on the efficacy of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, and on the excretion rate, pharmaceutical combination and severity of the particular disorder to which the therapy relates. Oral administration is preferred.
The following examples relate to pharmaceutical preparations:
Example A: Injection vials
A solution of 100 g of an active compound of the formula I and 5 g of disodium hydrogen phosphate is adjusted to pH 6.5 in 3 I of double-distilled water using 2 N hydrochloric acid, sterile-filtered, filled into injection vials and lyophilized under sterile conditions, and the vials are aseptically sealed. Each injection vial contains 5 mg of active compound.
Example B: Suppositories
A mixture of 20 g of an active compound of the formula I is fused with 100 g of soya lecithin and 1400 g of cocoa butter, poured into moulds and allowed to cool. Each suppository contains 20 mg of active compound.
Example C: Solution
A solution is prepared from 1 g of an active compound of the formula I, 9.38 g of NaH2P04.2H20, 28.48 g of Na2HP04.12H20 and 0.1 g of benzalkonium chloride in 940 ml of double-distilled water. The pH is adjusted to 6.8, and the solution is made up to 1 I and sterilized by irradiation.
Example D: Ointment
500 mg of an active compound of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
Example E: Tablets
A mixture of 1 kg of active compound of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed in a customary manner to give tablets in such a way that each tablet contains 10 mg of active compound. Example F: Coated tablets
Analogously to Example E, tablets are pressed which are then coated in a customary manner with a coating of sucrose, potato starch, talc, tragacanth and colourant.
Example G: Capsules
2 kg of active compound of the formula I are filled in a customary manner into hard gelatin capsules such that each capsule contains 20 mg of the active compound.
Example H: Ampoules
A solution of 1 kg of active compound of the formula I in 60 i of double- distilled water is steriie- filtered, filled into ampoules and lyophilized under sterile conditions, and the ampoules are aseptically sealed. Each ampoule contains 10 mg of active compound.

Claims

Patent Claims
se of benzoylguanidines of the formula
Figure imgf000017_0001
wherein
R1 is A,
R2 is Het, CnFmH2n+1-mOp, R4, OR4, OH, benzyl, CN, Hal,
SOq-R5, Ph, O-Ph, O-Het, NH-Het, NH2, NHA, NA2 or
NH-Ph, is S02A\ is a straight-chain or branched alkyl radical having 1 to 8
C atoms or cycloalkyl having 3 to 8 C atoms which can be unsubstituted or mono-, di- or trisubstituted by A,
R* is A or Ph, A, A in each case independently of one another are alkyl having 1 to 6 C atoms,
Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having from 1 to 4 N, O and/or S atoms, which can be substituted once, twice or three times by
Hal, CF3, A, CN, NO2, NH2 and/or carbonyl oxygen,
Hal is F, Cl, Br or I,
Ph is unsubstituted phenyl or substituted once, twice or three times by A, OA, Hal, CF3, NH2, NHA or NA2, m is 1 , 2, 3, 4, 5, 6, 7, but at most 2n+1 , n is 1 , 2 or 3,
P is 0 or 1 , q is 0, 1 or 2, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin- dependent diabetes mellitus.
2. Use of benzoylguanidines of the formula I according to claim 1 wherein the compounds are selected from the group a) N-diaminomethylene-2-methyl-4-(1-pyrrolyl)-5- methyisulfonylbenzamide, b) N-diaminomethylene-2-methyl-4-trifluoromethyl-5- methylsulfonylbenzamide, c) N-diaminomethylene-2-methyl-4-isopropyl-5- methylsulfonyibenzamide, and/or their physiologically acceptable salts and solvates for the production of a medicament for the treatment of non-insulin- dependent diabetes mellitus.
3. Phamaceutical preparation for the treatment of non-insulin- dependent diabetes mellitus, characterized in that it contains at least one compound of the general formula I according to claim 1 and/or one of its physiologically salts or solvates.
4. Phamaceutical preparation according to claim 3 for the treatment of non-insulin-dependent diabetes mellitus, characterized in that it contains at least one compound selected from the group a) N-diaminomethylene-2-methyl-4-(1 -pyrrolyl)-5- methyisulfonylbenzamide, b) N-diaminomethylene-2-methyl-4-trifluoromethyl-5- methylsulfonylbenzamide, c) N-diaminomethylene-2-methyl-4-isopropyl-5- methylsulfonylbenzamide, and/or one of its physiologically salts or solvates.
PCT/EP1999/008795 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus WO2000030624A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
HU0104418A HUP0104418A2 (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
AU15535/00A AU1553500A (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
JP2000583507A JP2002530325A (en) 1998-11-26 1999-11-16 Use of benzoylguanidine for the treatment of non-insulin-dependent diabetes mellitus
CA002352154A CA2352154A1 (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
BR9915667-9A BR9915667A (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
KR1020017006615A KR20010080597A (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
EP99958047A EP1131064A2 (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
NO20012563A NO20012563D0 (en) 1998-11-26 2001-05-25 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98122419 1998-11-26
EP98122419.9 1998-11-26

Publications (2)

Publication Number Publication Date
WO2000030624A2 true WO2000030624A2 (en) 2000-06-02
WO2000030624A3 WO2000030624A3 (en) 2000-10-05

Family

ID=8233036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008795 WO2000030624A2 (en) 1998-11-26 1999-11-16 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus

Country Status (14)

Country Link
EP (1) EP1131064A2 (en)
JP (1) JP2002530325A (en)
KR (1) KR20010080597A (en)
CN (1) CN1328452A (en)
AR (1) AR023064A1 (en)
AU (1) AU1553500A (en)
BR (1) BR9915667A (en)
CA (1) CA2352154A1 (en)
CZ (1) CZ20011785A3 (en)
HU (1) HUP0104418A2 (en)
ID (1) ID29523A (en)
NO (1) NO20012563D0 (en)
PL (1) PL348152A1 (en)
WO (1) WO2000030624A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050830A1 (en) * 2004-11-13 2006-05-18 Sanofi-Aventis Deutschland Gmbh Substituted benzoylguanidines method for production and use thereof as medicament or diagnostic and medicament comprising the same
US7381841B2 (en) 2003-08-22 2008-06-03 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100379410C (en) * 2002-06-05 2008-04-09 株式会社医药分子设计研究所 Therapeutic drug for diabetes

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699666A1 (en) * 1994-08-31 1996-03-06 MERCK PATENT GmbH Heterocyclic substituted benzoylguanidine
EP0699663A1 (en) * 1994-08-31 1996-03-06 MERCK PATENT GmbH Alkyl-benzoylguanidine derivatives
EP0708088A1 (en) * 1994-10-22 1996-04-24 MERCK PATENT GmbH Alkyl-5-methylsulphonyl-benzoyl-guanidine derivatives
EP0723963A1 (en) * 1995-01-28 1996-07-31 MERCK PATENT GmbH 4-amino-benzoylguanidine derivatives
EP0725062A1 (en) * 1995-01-31 1996-08-07 MERCK PATENT GmbH 4-mercapto-benzoylguanidine derivatives
EP0743301A2 (en) * 1995-05-16 1996-11-20 MERCK PATENT GmbH Benzoylguanidines containing fluorine
EP0760365A2 (en) * 1995-08-24 1997-03-05 MERCK PATENT GmbH Alkenyl-benzoylguanidines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699666A1 (en) * 1994-08-31 1996-03-06 MERCK PATENT GmbH Heterocyclic substituted benzoylguanidine
EP0699663A1 (en) * 1994-08-31 1996-03-06 MERCK PATENT GmbH Alkyl-benzoylguanidine derivatives
EP0708088A1 (en) * 1994-10-22 1996-04-24 MERCK PATENT GmbH Alkyl-5-methylsulphonyl-benzoyl-guanidine derivatives
EP0723963A1 (en) * 1995-01-28 1996-07-31 MERCK PATENT GmbH 4-amino-benzoylguanidine derivatives
EP0725062A1 (en) * 1995-01-31 1996-08-07 MERCK PATENT GmbH 4-mercapto-benzoylguanidine derivatives
EP0743301A2 (en) * 1995-05-16 1996-11-20 MERCK PATENT GmbH Benzoylguanidines containing fluorine
EP0760365A2 (en) * 1995-08-24 1997-03-05 MERCK PATENT GmbH Alkenyl-benzoylguanidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAUMGARTH M ET AL: "(2-Methyl-5(methylsufonyl)benzoyl) guanidine Na+/H+ antiporter inhibitors" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 40, no. 13, 20 June 1997 (1997-06-20), pages 2017-2034-34, XP002121770 ISSN: 0022-2623 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381841B2 (en) 2003-08-22 2008-06-03 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
WO2006050830A1 (en) * 2004-11-13 2006-05-18 Sanofi-Aventis Deutschland Gmbh Substituted benzoylguanidines method for production and use thereof as medicament or diagnostic and medicament comprising the same
US7772262B2 (en) 2004-11-13 2010-08-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylguanidines, method for production and use thereof as medicament or diagnostic and medicament comprising the same

Also Published As

Publication number Publication date
WO2000030624A3 (en) 2000-10-05
HUP0104418A2 (en) 2002-04-29
ID29523A (en) 2001-09-06
CZ20011785A3 (en) 2001-10-17
PL348152A1 (en) 2002-05-06
NO20012563L (en) 2001-05-25
CA2352154A1 (en) 2000-06-02
JP2002530325A (en) 2002-09-17
CN1328452A (en) 2001-12-26
KR20010080597A (en) 2001-08-22
BR9915667A (en) 2001-08-14
AU1553500A (en) 2000-06-13
NO20012563D0 (en) 2001-05-25
EP1131064A2 (en) 2001-09-12
AR023064A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
US6806268B2 (en) Method for treating glaucoma V
EP1025847B1 (en) Neovascularization promoters and neovascularization potentiators
US20090036465A1 (en) Combination therapy for pulmonary arterial hypertension
EP2314299A1 (en) Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin
KR101333990B1 (en) Agent for prevention or treatment of glaucoma
EP1902731A1 (en) Preventive or remedy for glaucoma
KR19990007985A (en) Use of α1L-agonist to treat incontinence
JP2007505083A (en) Benzothiazole derivatives for the treatment of diabetes
KR0148645B1 (en) Cardiac protective
JP2019081810A (en) Aqueous composition ii
US11331311B2 (en) Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
EP1147772B1 (en) Use of 1,4-benzothiazepine derivatives for the preparation of a medicament FOR the TREATMENT OF ATRIAL FIBRILLATION
JP2009001591A (en) Deprenyl compound for treatment of glaucoma
EP1131064A2 (en) Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
EP1004304A1 (en) Composition containing ascorbic acid
US20220387372A1 (en) Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
EP0930881A1 (en) Pyrazolinones to treat disturbances of potency
WO1993012796A1 (en) Use of renin inhibitors for the treatment of glaucoma
KR101333970B1 (en) Preventing or treating agent for glaucoma
MXPA01005295A (en) Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus
KR20020066959A (en) An agent for improving hypoalbuminaemia
CN100398102C (en) Drug for kidney failure containing oxaluric acid derivative
DE10129508A1 (en) Treatment of tumors originating from genomic alterations in p53 and pRb, using sodium ion-hydrogen ion (Na+/H+) antiporter inhibitors, preferably benzoyl-guanidine derivatives
US4514413A (en) Gastric acid secretion inhibiting N-(imidazol-1-ylalkyl)thiourea derivatives
Hoyng et al. Does prostacyclin mediate alpha-adrenergic induced hypotension?

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813826.6

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 15535

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999958047

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7002001

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2001-1785

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 09856547

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2352154

Country of ref document: CA

Ref document number: 2352154

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 583507

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005295

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017006615

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/648/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200105217

Country of ref document: ZA

Ref document number: 15535/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200100599

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020017006615

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999958047

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1785

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1999958047

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999958047

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-1785

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017006615

Country of ref document: KR